Aligos Therapeutics (NASDAQ:ALGS) Upgraded at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Aligos Therapeutics (NASDAQ:ALGS) to a strong-buy rating in a report issued on Wednesday morning,Zacks.com reports.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Aligos Therapeutics in a report on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. UBS Group started coverage on Aligos Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $20.00 target price for the company. Finally, Wall Street Zen lowered Aligos Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $39.33.

Aligos Therapeutics Trading Down 7.2%

Shares of Aligos Therapeutics stock opened at $6.81 on Wednesday. The firm has a fifty day simple moving average of $7.48 and a 200-day simple moving average of $8.87. The stock has a market capitalization of $42.15 million, a price-to-earnings ratio of -0.79 and a beta of 2.67. Aligos Therapeutics has a 1-year low of $3.76 and a 1-year high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.09) by $0.18. The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.27 million. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 28.16%. As a group, research analysts predict that Aligos Therapeutics will post -10.36 earnings per share for the current year.

Institutional Trading of Aligos Therapeutics

A number of institutional investors have recently modified their holdings of ALGS. Woodline Partners LP acquired a new position in shares of Aligos Therapeutics during the first quarter worth about $2,602,000. Marshall Wace LLP bought a new position in shares of Aligos Therapeutics during the fourth quarter worth about $2,504,000. Sio Capital Management LLC raised its position in Aligos Therapeutics by 85.9% in the 2nd quarter. Sio Capital Management LLC now owns 335,937 shares of the company’s stock valued at $2,422,000 after buying an additional 155,217 shares during the last quarter. SummitTX Capital L.P. acquired a new stake in Aligos Therapeutics in the 4th quarter valued at approximately $1,299,000. Finally, Verition Fund Management LLC bought a new stake in Aligos Therapeutics in the 4th quarter valued at approximately $664,000. 60.43% of the stock is currently owned by institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.